Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleSystemic Lupus Erythematosus

Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study

Mara Taraborelli, Rossella Reggia, Francesca Dall’Ara, Micaela Fredi, Laura Andreoli, Maria Gerosa, Ariela Hoxha, Laura Massaro, Marta Tonello, Nathalie Costedoat-Chalumeau, Patrice Cacoub, Franco Franceschini, Pier Luigi Meroni, Jean Charles Piette, Amelia Ruffatti, Guido Valesini, Eon Nigel Harris and Angela Tincani
The Journal of Rheumatology August 2017, 44 (8) 1165-1172; DOI: https://doi.org/10.3899/jrheum.161364
Mara Taraborelli
From the Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia, Brescia; Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milan; Rheumatology Unit, Department of Medicine - DIMED, University of Padua, Padua; Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy; AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, Service de Médecine Interne; AP-HP, Hospital Pitié-Salpêtrière, Centre de référence maladies auto-immunes et systémiques rares, Service de Médecine Interne, Pierre et Marie Curie Paris VI University, Paris, France; University of the West Indies, Kingston, Jamaica.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rossella Reggia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Dall’Ara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Micaela Fredi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Andreoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Gerosa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariela Hoxha
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Massaro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Tonello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Costedoat-Chalumeau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Cacoub
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franco Franceschini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Luigi Meroni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Charles Piette
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amelia Ruffatti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guido Valesini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eon Nigel Harris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Tincani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: angela.tincani{at}unibs.it
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Treatment flow diagram. (A) Treatment at the time of 75 thrombotic events in 51 patients during followup. (B) Involvement of oral anticoagulant in 84 patients with a thrombotic disease onset. OA: oral anticoagulant; INR: international normalized ratio; LMWH: low molecular weight heparin; HCQ: hydroxychloroquine.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Treatment flow diagram. (A) Treatment at the time of 75 thrombotic events in 51 patients during followup. (B) Involvement of oral anticoagulant in 84 patients with a thrombotic disease onset. OA: oral anticoagulant; INR: international normalized ratio; LMWH: low molecular weight heparin; HCQ: hydroxychloroquine.

  • Time (months) to first recurrence in patients with previous thrombosis according to the use and non-use of OA (Kaplan-Meier analysis). OA: oral anticoagulants.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Time (months) to first recurrence in patients with previous thrombosis according to the use and non-use of OA (Kaplan-Meier analysis). OA: oral anticoagulants.

Tables

  • Figures
    • View popup
    Table 1.

    List of the items collected from clinical charts.

    ItemsDescription
    DemographicsSex, race, age, duration of followup
    DiagnosisAccording to the most recent international classification criteria
    APS clinical manifestationsAs previously described5. Non-criteria manifestations defined as those not included in the updated classification criteria4, including cardiac: valvular disease, systolic dysfunction, pulmonary hypertension; pulmonary: acute respiratory distress syndrome, hemorrhagic alveolitis; central nervous system: transient ischemic attack, severe headache, epileptic seizures, cognitive dysfunctions, white matter lesions, transverse myelitis, movement disorders; renal: renal arterial stenosis, thrombotic microangiopathy; cutaneous: livedo reticularis, ulcers, digital gangrene, subungual splinter hemorrhages; ocular: ischemic optical neuritis; endocrinological: hyperprolactinemia, hyposurrenalism; hematological: thrombocytopenia, hemolytic anemia; osteoarticular: osteonecrosis, bone infarct.
    Serologic changes*LABy coagulation assay
    IgG-IgM aCLBy ELISA
    IgG-IgM anti-β2-GPIBy ELISA
    ANABy indirect immunofluorescence on Hep-2 cells substrate (≥ 1:160)
    Anti-dsDNABy Farr ammonium sulfate precipitation technique, ELISA, and/or indirect immunofluorescence on Crithidia luciliae substrate
    Anti-ENABy ELISA or by homemade counter-immunoelectrophoresis using calf and rabbit thymus and human spleen extracts
    C3, C4By nephelometry and/or immunoturbidimetry and/or radial immunodiffusion
    Cardiovascular risk factorsHormonal therapyEstroprogestinic pill or hormonal replacement therapy
    ObesityBody mass index ≥ 30
    SmokingPresent use of cigarettes
    Diabetes mellitusAny previous diagnosis of diabetes or 2 glycemia tests ≥ 126 mg/dl
    HypercholesterolemiaTotal cholesterol blood levels ≥ 200 mg/dl
    HyperhomocysteinemiaBlood homocysteine above the normal limit
    Systemic arterial hypertensionArterial blood pressure ≥ 140/90 mmHg
    Inherited thrombophiliaAntithrombin or protein C or protein S deficiency, factor V Leiden or prothrombin or methylenetetrahydrofolate reductase mutation
    CancerAny solid or hematological neoplasm diagnosis
    TherapyEach drug taken for at least 3 mos at any point during followup
    Severe comorbiditiesSevere infectionsRequiring hospitalization
    Severe hemorrhagesFatal or requiring hospitalization/treatment withdrawal
    CancerAny solid or hematological neoplasm diagnosis
    Functional damagePermanent loss of function in any organ or system because of APS
    • ↵* Only confirmed serological positivity was considered (at least 2 determinations, for antiphospholipid antibodies at least 12 weeks apart). APS: antiphospholipid syndrome; LA: lupus anticoagulant; Ig: immunoglobulin; aCL: anticardiolipin antibodies; anti-β2-GPI: anti-β2 glycoprotein I antibodies; ANA: antinuclear antibodies; anti-ENA: antiextractable nuclear antigens antibodies; C3 and C4: complement fractions.

    • View popup
    Table 2.

    Serological characteristics and cardiovascular risk factors: comparison between diagnosis and end of followup. Values are n (%) unless otherwise specified.

    FeatureDiagnosisEnd of Followup*p, Chi-square
    LA positivity78/107 (73)55/85 (65)0.29
    aCL-IgG positivity103/115 (90)89/115 (77)0.02
    aCL-IgM positivity54/115 (47)40/115 (35)0.08
    Anti-β2-GPI-IgG positivity64/98 (65)82/115 (71)0.43
    Anti-β2-GPI-IgM positivity40/98 (41)45/115 (39)0.91
    Single aPL positivity22/90 (24)10/85 (12)0.03
    Double aPL positivity17/90 (19)13/85 (15)0.67
    Triple aPL positivity51/90 (57)48/85 (57)0.98
    Negative aPL0/90 (0)14/85 (16)< 0.001
    ANA positivity60/115 (52)70/115 (61)0.23
    Anti-dsDNA positivity18/115 (16)13/115 (11)0.31
    Anti-ENA positivity12/115 (10)20/115 (17)0.11
    Isolated low C315/108 (14)16/111 (14)1.00
    Isolated low C49/108 (8)8/111 (7)0.95
    Low C3 and C412/108 (11)15/111 (14)0.74
    Hormonal therapy23/101 (23)2/101 (2)< 0.001
    Obesity, BMI > 3011/115 (10)17/115 (15)0.31
    Smoking27/115 (23)18/115 (16)0.18
    Diabetes mellitus2/115 (2)7/115 (6)0.17
    Hypercholesterolemia26/115 (23)41/115 (36)0.042
    Hyperhomocysteinemia12/85 (14)24/113 (21)0.27
    Systemic arterial hypertension23/115 (20)44/115 (38)0.004
    Inherited thrombophilia**26/103 (25)26/103 (25)1.00
    Cancer1/115 (1)8/115 (7)0.041
    • ↵* The last 2 determinations (at least 12 weeks apart for aPL) available at the end of the followup were considered.

    • ↵** Seven patients with heterozygous methylene tetrahydrofolate reductase mutation, 10 with homozygous methylene tetrahydrofolate reductase mutation, 3 with heterozygous factor II mutation, 3 with heterozygous factor V mutation, 5 with protein S deficiency, 2 with protein C deficiency, 2 with antithrombin deficiency. Significant data are in bold face. LA: lupus anticoagulant; aCL: anticardiolipin antibodies; Ig: immunoglobulins; anti-β2-GPI: anti-β2 glycoprotein I antibodies; aPL: antiphospholipid antibodies; ANA: antinuclear antibodies; anti-ENA: antiextractable nuclear antigens antibodies; C3 and C4: complement fractions 3 and 4; BMI: body mass index.

    • View popup
    Table 3.

    Treatment at diagnosis and cumulative use during the followup. Values are n (%) unless otherwise specified.

    TherapyDiagnosisDuring Followupp, Chi-square
    Corticosteroids*34/115 (30)49/115 (43)0.06
    Hydroxychloroquine4/115 (3)52/115 (45)< 0.001
    Immunosuppressants**1/115 (1)16/115 (14)< 0.001
    Antiplatelet agents54/115 (47)68/115 (59)0.09
    Oral anticoagulant62/115 (54)77/115 (67)0.06
    Antihypertensive drugs22/115 (19)51/115 (44)< 0.001
    • ↵* Used during pregnancy in most cases.

    • ↵** Azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, and methotrexate. Significant data are in bold face.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 44, Issue 8
1 Aug 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study
Mara Taraborelli, Rossella Reggia, Francesca Dall’Ara, Micaela Fredi, Laura Andreoli, Maria Gerosa, Ariela Hoxha, Laura Massaro, Marta Tonello, Nathalie Costedoat-Chalumeau, Patrice Cacoub, Franco Franceschini, Pier Luigi Meroni, Jean Charles Piette, Amelia Ruffatti, Guido Valesini, Eon Nigel Harris, Angela Tincani
The Journal of Rheumatology Aug 2017, 44 (8) 1165-1172; DOI: 10.3899/jrheum.161364

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study
Mara Taraborelli, Rossella Reggia, Francesca Dall’Ara, Micaela Fredi, Laura Andreoli, Maria Gerosa, Ariela Hoxha, Laura Massaro, Marta Tonello, Nathalie Costedoat-Chalumeau, Patrice Cacoub, Franco Franceschini, Pier Luigi Meroni, Jean Charles Piette, Amelia Ruffatti, Guido Valesini, Eon Nigel Harris, Angela Tincani
The Journal of Rheumatology Aug 2017, 44 (8) 1165-1172; DOI: 10.3899/jrheum.161364
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Keywords

PRIMARY ANTIPHOSPHOLIPID SYNDROME
RECURRENCES
PREGNANCY
EVOLUTION
ORGAN DAMAGE
THROMBOSIS

Related Articles

Cited By...

More in this TOC Section

  • Comparative Performance of SLECRISK and PREVENT for Cardiovascular Risk Prediction in Systemic Lupus Erythematosus
  • Qualitative Analysis of Physical Activity Engagement in Women With Self-Reported Systemic Lupus Erythematosus: The Role of Symptoms, Healthcare Providers, and the Environment
  • Association of Daily Glucocorticoid Dose With Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Data From the Almenara Lupus Cohort
Show more Systemic Lupus Erythematosus

Similar Articles

Keywords

  • PRIMARY ANTIPHOSPHOLIPID SYNDROME
  • RECURRENCES
  • pregnancy
  • EVOLUTION
  • ORGAN DAMAGE
  • THROMBOSIS

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire